Follow The Filings

ANAB Anaptysbio Inc.

Health Care, filed as ANAPTYSBIO INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 2 Owners
  • Max 7.5%
  • $52M
  • 1 new 1 reduce

In 2026 Q2 Scott Miller opened a position in Anaptysbio, while Palo Alto Investors trimmed.

Who owns this now

Largest portfolio weights among holders, up to 7.5% (Scott Miller, Greenhaven Road Investment Management). Not free-float ownership.

  1. Scott Miller New 7.5%
  2. Palo Alto Investors Reduce 5.6%

Who owns ANAB

Sorted by value, long equity only, as of 2026 Q2.

History
Palo Alto Investors 5.6% Reduce −5.4% 603,489 $41M History
Scott Miller, Greenhaven Road Investment Management 7.5% New 7.5% 171,059 $12M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ANAB's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ANAB insider trades
  • None no insider bought on the open market
  • $1.9M sold by 3 insiders outside a trading plan
  • $4M sold by 4 insiders under 10b5-1 plans
  1. Hollings Renton Director
    Planned sale
    $249K 5,000 shares at $49.87 31% of stake
    Traded Oct 1 Filed Oct 2
    ↗
  2. John P. Schmid Director
    Sale
    $1.2M 20,645 shares at $56.11 40% of stake
    Traded Mar 30 Filed Apr 1
    ↗
  3. Eric J Loumeau Chief Legal Officer
    Planned sale
    $540K 10,000 shares at $54.00 44% of stake
    Traded Feb 11 Filed Feb 13
    ↗
  4. Magda Marquet Director
    Sale
    $531K 11,000 shares at $48.23 53% of stake
    Traded Jan 15 Filed Jan 16
    ↗
  5. Eric J Loumeau Chief Legal Officer
    Planned sale
    $348K 7,622 shares at $45.69 45% of stake
    Traded Jan 7 Filed Jan 8
    ↗
  6. J. Anthony Ware Director
    Sale
    $193K 3,900 shares at $49.58 29% of stake
    Traded Dec 23, 2025 Filed Dec 23, 2025
    ↗
  7. Paul F. Lizzul Chief Medical Officer
    Planned sale
    $75K 1,500 shares at $50.00 5.3% of stake
    Traded Dec 22, 2025 Filed Dec 23, 2025
    ↗
  8. Dennis Mulroy CFO
    Planned sale
    $500K 10,000 shares at $50.00 52% of stake
    Traded Dec 22, 2025 Filed Dec 23, 2025
    ↗
  9. Eric J Loumeau Chief Legal Officer
    Planned sale
    $510K 10,000 shares at $51.00 53% of stake
    Traded Dec 22, 2025 Filed Dec 23, 2025
    ↗
  10. Dennis Mulroy CFO
    Planned sale
    $705K 15,725 shares at $44.85 63% of stake
    Traded Dec 16, 2025 Filed Dec 18, 2025
    ↗
  11. Eric J Loumeau Chief Legal Officer
    Planned sale
    $1M 22,641 shares at $45.38 72% of stake
    Traded Dec 16–18 Filed Dec 18, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 26 option exercises, 22 sales to cover taxes, 1 stock grant, and 1 other transaction.

SEC filings

Recent issuer filings from EDGAR, 21 shown.

Filed Form Detail Links
8-K 9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.07,9.01 Filing Doc
8-K 7.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 1.01 Filing Doc
8-K 7.01 Filing Doc
8-K 5.03 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02 Filing Doc
10-K/A Filing Doc
8-K/A 9.01 Filing Doc
8-K 1.01,2.01,5.02,8.01,9.01 Filing Doc
8-K 1.01,1.02,5.02,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-K Filing Doc

Source: SEC EDGAR submissions, updated 12 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $17.16M $91.28M $234.6M
Net income -$163.62M -$145.23M -$13.23M
Net margin * -953.7% -159.1% -5.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $406.84M $431.88M $350.25M
Total non-current assets * $45.55M $51.96M $14.14M
Total assets $452.39M $483.83M $364.4M
Total current liabilities $37.44M $45.43M $38.62M
Total equity $88.1M $70.87M $37.21M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$120.8M -$135.34M $19.7M
Cash from investing $144.75M $95.4M $228.03M
Cash from financing -$59.3M $127.05M -$132.61M
Net change in cash -$35.34M $87.12M $115.12M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.